Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	MK2206	2	72	sigmoid	sigmoid	HCC38 MK-2206 0 2 72	8	2.159	Inf	0.788	0.0476	0.776	0.775	1.99	0.972	2.1e-05	NA	Inf	0.785	0.951	0.752	0.772	1.98	0.969	2.9e-05	NA
HCC38	MK2206	3	72	sigmoid	sigmoid	HCC38 MK-2206 0 3 72	8	1.445	71.7	0.728	0.123	320.0	-0.26	0.28	0.854	0.0031	NA	Inf	0.81	0.912	4.3	0.61	0.332	0.834	0.00461	NA
HCC38	Omipalisib	1	72	sigmoid	sigmoid	HCC38 omipalisib 0 1 72	8	1.760	0.0231	-0.316	0.672	0.152	-0.638	0.438	0.97	2.61e-05	NA	0.0585	0.151	0.512	0.0499	0.0356	0.465	0.956	8.65e-05	NA
HCC38	Omipalisib	2	72	sigmoid	sigmoid	HCC38 omipalisib 0 2 72	8	2.124	0.0404	-0.47	0.634	0.45	-1.0	0.456	0.979	9.71e-06	NA	0.0507	0.0595	0.494	0.0507	0.0	0.556	0.96	6.44e-05	NA
HCC38	Omipalisib	3	72	sigmoid	sigmoid	HCC38 omipalisib 0 3 72	8	1.446	0.0145	-0.503	0.802	0.0539	-0.597	0.6	0.993	3.08e-07	NA	0.0449	0.134	0.499	0.0308	0.107	0.644	0.993	2.98e-07	NA
HCC38	PI103	1	72	sigmoid	sigmoid	HCC38 PI-103 0 1 72	8	1.782	0.755	0.222	0.201	0.601	0.12	1.2	0.996	4.45e-08	NA	1.39	0.416	0.839	0.494	0.359	1.23	0.995	1.01e-07	NA
HCC38	PI103	2	72	sigmoid	sigmoid	HCC38 PI-103 0 2 72	8	2.094	0.856	0.226	0.167	0.672	0.135	1.3	0.986	2.7e-06	NA	1.04	0.359	0.851	0.488	0.33	1.43	0.981	6.52e-06	NA
HCC38	PI103	3	72	sigmoid	sigmoid	HCC38 PI-103 0 3 72	8	1.481	1.26	0.114	0.168	3.16	-0.762	1.01	0.986	2.53e-06	NA	2.34	0.42	0.884	2.34	0.0	1.03	0.983	4.94e-06	NA
HCC38	Pictilisib	1	72	sigmoid	sigmoid	HCC38 pictilisib 0 1 72	8	1.759	7.16	0.562	0.125	1.04	0.377	0.725	0.992	5.12e-07	NA	Inf	0.647	0.896	0.797	0.529	0.742	0.992	5.77e-07	NA
HCC38	Pictilisib	2	72	sigmoid	sigmoid	HCC38 pictilisib 0 2 72	8	2.112	Inf	0.622	0.0838	0.644	0.58	1.32	0.933	0.000298	NA	Inf	0.642	0.918	0.568	0.612	1.36	0.922	0.000475	NA
HCC38	Pictilisib	3	72	sigmoid	sigmoid	HCC38 pictilisib 0 3 72	8	1.420	3.12	0.499	0.129	2.45	0.0818	0.738	0.976	1.33e-05	NA	20.5	0.664	0.911	2.24	0.401	0.731	0.974	1.7e-05	NA
HCC38	PIK-93	1	72	sigmoid	sigmoid	HCC38 PIK-93 0 1 72	8	1.741	5.24	0.61	0.0782	24.5	-1.0	0.713	0.982	6.07e-06	NA	9.93	0.686	0.935	9.93	0.0	0.729	0.979	9.08e-06	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC38	PIK-93	3	72	sigmoid	sigmoid	HCC38 PIK-93 0 3 72	8	1.382	5.05	0.598	0.061	2.34	0.358	1.63	0.919	0.000533	NA	Inf	0.734	0.959	2.23	0.586	1.64	0.914	0.000645	NA
HCC38	XL147	1	72	flat	flat	HCC38 pilaralisib 0 1 72	8	1.752	Inf	0.949	0.0257	0.0	0.949	0.01	-0.0703	1.0	0.973	Inf	0.955	0.978	0.0	0.955	0.01	-0.0701	1.0	0.977
HCC38	XL147	2	72	flat	flat	HCC38 pilaralisib 0 2 72	8	2.194	Inf	0.938	0.0288	0.0	0.938	0.01	-0.0925	1.0	0.968	Inf	0.933	0.969	0.0	0.933	0.01	-0.0418	1.0	0.965
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
HCC38	Sirolimus	1	72	flat	flat	HCC38 rapamycin 0 1 72	8	1.723	Inf	0.531	0.429	0.0	0.531	0.01	0.623	0.0538	0.573	Inf	0.631	0.66	0.0	0.631	0.01	0.536	0.0998	0.661
HCC38	Sirolimus	2	72	flat	flat	HCC38 rapamycin 0 2 72	8	2.106	Inf	0.588	0.371	0.0	0.588	0.01	0.496	0.128	0.629	Inf	0.616	0.65	0.0	0.616	0.01	0.246	0.429	0.649
HCC38	Sirolimus	3	72	sigmoid	sigmoid	HCC38 rapamycin 0 3 72	8	1.420	86.3	0.535	0.403	0.000236	0.361	0.1	0.901	0.000982	NA	75575.0	0.687	0.727	0.000198	0.569	0.1	0.889	0.00136	NA
HCC38	TGX221	1	72	sigmoid	sigmoid	HCC38 TGX-221 0 1 72	8	1.724	Inf	0.938	0.0116	0.289	0.941	5.0	0.676	0.0342	NA	Inf	0.947	0.99	0.289	0.949	5.0	0.672	0.0354	NA
HCC38	TGX221	2	72	sigmoid	sigmoid	HCC38 TGX-221 0 2 72	8	2.116	Inf	0.908	0.0281	4.57	0.803	0.501	0.711	0.0242	NA	Inf	0.905	0.971	4.56	0.797	0.497	0.705	0.0256	NA
HCC38	TGX221	3	72	sigmoid	sigmoid	HCC38 TGX-221 0 3 72	8	1.484	3688.0	0.815	0.0743	320.0	0.243	0.273	0.867	0.00233	NA	3261706.0	0.866	0.945	320.0	0.458	0.269	0.867	0.00238	NA
HCC38	Torin1	1	72	sigmoid	sigmoid	HCC38 Torin1 0 1 72	8	1.688	0.0287	-0.0113	0.569	0.0278	0.013	0.843	0.993	4.14e-07	NA	0.0653	0.304	0.585	0.0204	0.325	0.9	0.992	4.53e-07	NA
HCC38	Torin1	2	72	sigmoid	sigmoid	HCC38 Torin1 0 2 72	8	2.136	0.0241	0.0393	0.573	0.0203	0.0651	0.82	0.995	1.24e-07	NA	0.0309	0.247	0.512	0.013	0.267	0.88	0.996	4.87e-08	NA

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)